Literature DB >> 12504077

Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells.

Jill E Clampit1, Joseph L Meuth, Harriet T Smith, Regina M Reilly, Michael R Jirousek, James M Trevillyan, Cristina M Rondinone.   

Abstract

Protein-tyrosine phosphatase-1B (PTP1B) has been implicated as a negative regulator of insulin signaling. PTP1B dephosphorylates the insulin receptor and insulin receptor substrates (IRS-1/2), inhibiting the insulin-signaling pathway. PTP1B has been reported to be elevated in diabetes and insulin-resistant states. Conversely, PTP1B null mice have increased insulin sensitivity. To further investigate the effect of PTP1B reduction on insulin signaling, FAO rat hepatoma cells were transfected, by electroporation, with a specific PTP1B antisense oligonucleotide (ASO), or a control oligonucleotide. The PTP1B ASO caused a 50-70% reduction in PTP1B protein expression as measured by Western blot analysis. Upon insulin stimulation, an increase in the phosphorylation of the insulin receptor and insulin receptor substrates was observed, without any change in protein expression levels. Reduction of PTP1B expression in FAO cells also caused an increase in insulin-stimulated phosphorylation of PKB and GSK3, without any change in protein expression. These results demonstrate that reduction of PTP1B can modulate key insulin signaling events downstream of the insulin receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504077     DOI: 10.1016/s0006-291x(02)02839-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Insulin receptor substrate 2 (IRS2)-deficient mice show sensorineural hearing loss that is delayed by concomitant protein tyrosine phosphatase 1B (PTP1B) loss of function.

Authors:  Silvia Murillo-Cuesta; Guadalupe Camarero; Agueda González-Rodríguez; Lourdes Rodríguez De La Rosa; Deborah J Burks; Carlos Avendaño; Angela M Valverde; Isabel Varela-Nieto
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

2.  Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues.

Authors:  Bingzhong Xue; Thomas Pulinilkunnil; Incoronata Murano; Kendra K Bence; Huamei He; Yasuhiko Minokoshi; Kenji Asakura; Anna Lee; Fawaz Haj; Noboru Furukawa; Karyn J Catalano; Mirela Delibegovic; James A Balschi; Saverio Cinti; Benjamin G Neel; Barbara B Kahn
Journal:  Mol Cell Biol       Date:  2009-06-15       Impact factor: 4.272

Review 3.  Protein tyrosine phosphatases (PTPs) in diabetes: causes and therapeutic opportunities.

Authors:  Chiranjeev Sharma; Youllee Kim; Dohee Ahn; Sang J Chung
Journal:  Arch Pharm Res       Date:  2021-02-15       Impact factor: 4.946

4.  Rosiglitazone attenuates tumor necrosis factor-α-induced protein-tyrosine phosphatase-1B production in HepG2 cells.

Authors:  J Wu; L-J Yang; D-J Zou
Journal:  J Endocrinol Invest       Date:  2011-04-06       Impact factor: 4.256

5.  Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice.

Authors:  Agueda González-Rodríguez; Jose A Mas Gutierrez; Silvia Sanz-González; Manuel Ros; Deborah J Burks; Angela M Valverde
Journal:  Diabetes       Date:  2009-12-22       Impact factor: 9.461

6.  Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.

Authors:  Sijiu Liu; Li-Fan Zeng; Li Wu; Xiao Yu; Ting Xue; Andrea M Gunawan; Ya-Qiu Long; Zhong-Yin Zhang
Journal:  J Am Chem Soc       Date:  2008-12-17       Impact factor: 15.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.